Khona began with rare cannabinoids and a stubborn biological problem: long pathways leak value at every step. Now the four-person Colorado biotech is aiming its microbial assembly line at a larger prize - domestic supplies of pharmaceutical starting materials and APIs.
Sun Pharma became India’s largest drugmaker by mastering generics. Now a portfolio of skin, eye and cancer medicines - and an audacious pending Organon deal - is changing what the company wants to be.